Plain-English translation of NCT06429449 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Leukemia research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This clinical trial is testing whether adding —a chemotherapy drug—to your current leukemia treatment can help fight acute myeloid leukemia (AML) that didn't respond to or returned after your first round of therapy. The study will first figure out the safest and most effective dose of this medication when combined with your existing treatment, and then test it in a larger group of patients to see if it helps reduce cancer cells in your bone marrow.
Some patients with AML don't respond well enough to standard first-line treatment, and others see their cancer come back after initial success. This trial aims to find a new combination approach that might work better for these patients when the standard treatment isn't enough.
You likely qualify if…
You likely don't qualify if…
In the first phase of the study, you will receive the existing leukemia medications ( and ) plus increasing doses of given as an IV infusion on days 1-4 of your treatment cycle, with researchers carefully monitoring how you tolerate each dose level. If the study moves to the second phase and you qualify, you'll receive the determined safe dose combined with your regular medications, and doctors will check your bone marrow about 4 weeks later to see how well the treatment is working; if it's helping, you can continue with more cycles of the same treatment.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
University of Colorado, Denver
Collaborators
The Leukemia and Lymphoma Society
Enrollment target
~30 participants
Started
July 2024
Primary completion
December 2026
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Derek Schatz
University of Colorado, Denver
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.